View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsReNeuron Group 配当と自社株買い配当金 基準チェック /06ReNeuron Group配当金を支払った記録がありません。主要情報n/a配当利回り-0.05%バイバック利回り総株主利回り-0.05%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").お知らせ • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.お知らせ • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.Major Estimate Revision • Nov 28Consensus revenue estimates decrease by 28%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from UK£910.0k to UK£650.0k. EPS estimate increased from -UK£0.105 to -UK£0.091 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 25% next year. Consensus price target of UK£0.55 unchanged from last update. Share price rose 17% to UK£0.043 over the past week.New Risk • Nov 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Revenue is less than US$1m (UK£249k revenue, or US$306k). Market cap is less than US$10m (UK£3.05m market cap, or US$3.74m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change).お知らせ • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023お知らせ • Jul 25ReNeuron Group plc, Annual General Meeting, Aug 22, 2023ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United KingdomMajor Estimate Revision • Jun 01Consensus EPS estimates upgraded to UK£0.10 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -UK£0.14 to -UK£0.105 per share. Revenue forecast unchanged from UK£906.0k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 18% next year. Consensus price target down from UK£0.72 to UK£0.59. Share price fell 15% to UK£0.058 over the past week.Reported Earnings • May 26Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: UK£0.095 loss per share (improved from UK£0.17 loss in FY 2022). Net loss: UK£5.41m (loss narrowed 44% from FY 2022). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 21%.お知らせ • May 19ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023ReNeuron Group plc announced that they will report Q4, 2023 results on May 25, 2023Board Change • Apr 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Mike Owen is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 04+ 1 more updateReNeuron Group plc Appoints Iain Ross as Executive ChairmanReNeuron Group plc announced that Iain Ross, who has been on the Board since July 2021, has been appointed as Executive Chairman and will lead a restructuring of the business, with further announcements to be made in due course. He is an experienced industry executive who has led several successful biotech turnarounds, including more recently that of Redx Pharma plc and Silence Therapeutics plc.Major Estimate Revision • Dec 09Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 losses forecast to reduce from -UK£0.17 to -UK£0.13 per share. Revenue forecast unchanged from UK£685.3k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target of UK£0.79 unchanged from last update. Share price fell 27% to UK£0.11 over the past week.Reported Earnings • Dec 03First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)First half 2023 results: UK£0.056 loss per share (improved from UK£0.092 loss in 1H 2022). Net loss: UK£3.18m (loss narrowed 39% from 1H 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Breakeven Date Change • Nov 16No longer forecast to breakevenThe 3 analysts covering ReNeuron Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£22.8m in 2024. New consensus forecast suggests the company will make a loss of UK£10.3m in 2024.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Sep 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Aug 18Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 70%, compared to a 10% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.分析記事 • Jul 15We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...Price Target Changed • Jul 06Price target decreased to UK£2.22Down from UK£3.58, the current price target is provided by 1 analyst. New target price is 626% above last closing price of UK£0.30. Stock is down 72% over the past year. The company posted a net loss per share of UK£0.17 last year.Reported Earnings • Jul 04Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 53,796%, compared to a 160% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Price Target Changed • Jun 16Price target decreased to UK£2.19Down from UK£3.79, the current price target is an average from 3 analysts. New target price is 584% above last closing price of UK£0.32. Stock is down 73% over the past year. The company posted a net loss per share of UK£0.29 last year.Price Target Changed • Apr 27Price target decreased to UK£2.04Down from UK£3.02, the current price target is an average from 2 analysts. New target price is 459% above last closing price of UK£0.36. Stock is down 75% over the past year. The company posted a net loss per share of UK£0.29 last year.分析記事 • Jan 22We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...Price Target Changed • Jan 19Price target decreased to UK£2.04Down from UK£3.00, the current price target is an average from 2 analysts. New target price is 410% above last closing price of UK£0.40. Stock is down 68% over the past year. The company posted a net loss per share of UK£0.29 last year.Reported Earnings • Dec 02First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: UK£0.092 loss per share (up from UK£0.22 loss in 1H 2021). Net loss: UK£5.23m (loss narrowed 26% from 1H 2021). Revenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 55%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 20% per year.分析記事 • Oct 12Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Reported Earnings • Aug 22Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jul 09Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.分析記事 • Jun 04Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Jan 12Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Is New 90 Day High Low • Jan 07New 90-day high: UK£1.11The company is up 18% from its price of UK£0.94 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 16New 90-day low: UK£0.72The company is down 15% from its price of UK£0.85 on 16 September 2020. The British market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.Reported Earnings • Nov 26First half 2021 earnings released: UK£0.22 loss per shareFirst half 2021 results: Net loss: UK£7.09m (loss widened 82% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 24New 90-day low: UK£0.78The company is down 23% from its price of UK£1.01 on 26 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.分析記事 • Nov 20Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)Olav Hellebo has been the CEO of ReNeuron Group plc (LON:RENE) since 2014, and this article will examine the...決済の安定と成長配当データの取得安定した配当: RENEの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: RENEの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場ReNeuron Group 配当利回り対市場RENE 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (RENE)n/a市場下位25% (GB)2.2%市場トップ25% (GB)5.7%業界平均 (Biotechs)2.3%アナリスト予想 (RENE) (最長3年)0%注目すべき配当: RENEは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: RENEは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: RENEの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: RENEが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YGB 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/05/04 16:56終値2024/02/05 00:00収益2023/09/30年間収益2023/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ReNeuron Group plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関David Paul St. JohnsonAllenby Capital LimitedSoo RomanoffEdison Investment ResearchJason McCarthyMaxim Group2 その他のアナリストを表示
お知らせ • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").
お知らせ • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.
お知らせ • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.
Major Estimate Revision • Nov 28Consensus revenue estimates decrease by 28%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from UK£910.0k to UK£650.0k. EPS estimate increased from -UK£0.105 to -UK£0.091 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 25% next year. Consensus price target of UK£0.55 unchanged from last update. Share price rose 17% to UK£0.043 over the past week.
New Risk • Nov 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Revenue is less than US$1m (UK£249k revenue, or US$306k). Market cap is less than US$10m (UK£3.05m market cap, or US$3.74m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change).
お知らせ • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023
お知らせ • Jul 25ReNeuron Group plc, Annual General Meeting, Aug 22, 2023ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United Kingdom
Major Estimate Revision • Jun 01Consensus EPS estimates upgraded to UK£0.10 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -UK£0.14 to -UK£0.105 per share. Revenue forecast unchanged from UK£906.0k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 18% next year. Consensus price target down from UK£0.72 to UK£0.59. Share price fell 15% to UK£0.058 over the past week.
Reported Earnings • May 26Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: UK£0.095 loss per share (improved from UK£0.17 loss in FY 2022). Net loss: UK£5.41m (loss narrowed 44% from FY 2022). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 21%.
お知らせ • May 19ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023ReNeuron Group plc announced that they will report Q4, 2023 results on May 25, 2023
Board Change • Apr 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Mike Owen is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 04+ 1 more updateReNeuron Group plc Appoints Iain Ross as Executive ChairmanReNeuron Group plc announced that Iain Ross, who has been on the Board since July 2021, has been appointed as Executive Chairman and will lead a restructuring of the business, with further announcements to be made in due course. He is an experienced industry executive who has led several successful biotech turnarounds, including more recently that of Redx Pharma plc and Silence Therapeutics plc.
Major Estimate Revision • Dec 09Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 losses forecast to reduce from -UK£0.17 to -UK£0.13 per share. Revenue forecast unchanged from UK£685.3k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target of UK£0.79 unchanged from last update. Share price fell 27% to UK£0.11 over the past week.
Reported Earnings • Dec 03First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)First half 2023 results: UK£0.056 loss per share (improved from UK£0.092 loss in 1H 2022). Net loss: UK£3.18m (loss narrowed 39% from 1H 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Nov 16No longer forecast to breakevenThe 3 analysts covering ReNeuron Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£22.8m in 2024. New consensus forecast suggests the company will make a loss of UK£10.3m in 2024.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Sep 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Aug 18Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 70%, compared to a 10% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
分析記事 • Jul 15We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Price Target Changed • Jul 06Price target decreased to UK£2.22Down from UK£3.58, the current price target is provided by 1 analyst. New target price is 626% above last closing price of UK£0.30. Stock is down 72% over the past year. The company posted a net loss per share of UK£0.17 last year.
Reported Earnings • Jul 04Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 53,796%, compared to a 160% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Price Target Changed • Jun 16Price target decreased to UK£2.19Down from UK£3.79, the current price target is an average from 3 analysts. New target price is 584% above last closing price of UK£0.32. Stock is down 73% over the past year. The company posted a net loss per share of UK£0.29 last year.
Price Target Changed • Apr 27Price target decreased to UK£2.04Down from UK£3.02, the current price target is an average from 2 analysts. New target price is 459% above last closing price of UK£0.36. Stock is down 75% over the past year. The company posted a net loss per share of UK£0.29 last year.
分析記事 • Jan 22We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Price Target Changed • Jan 19Price target decreased to UK£2.04Down from UK£3.00, the current price target is an average from 2 analysts. New target price is 410% above last closing price of UK£0.40. Stock is down 68% over the past year. The company posted a net loss per share of UK£0.29 last year.
Reported Earnings • Dec 02First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: UK£0.092 loss per share (up from UK£0.22 loss in 1H 2021). Net loss: UK£5.23m (loss narrowed 26% from 1H 2021). Revenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 55%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 20% per year.
分析記事 • Oct 12Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Reported Earnings • Aug 22Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jul 09Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
分析記事 • Jun 04Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Jan 12Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Is New 90 Day High Low • Jan 07New 90-day high: UK£1.11The company is up 18% from its price of UK£0.94 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 16New 90-day low: UK£0.72The company is down 15% from its price of UK£0.85 on 16 September 2020. The British market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.
Reported Earnings • Nov 26First half 2021 earnings released: UK£0.22 loss per shareFirst half 2021 results: Net loss: UK£7.09m (loss widened 82% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 24New 90-day low: UK£0.78The company is down 23% from its price of UK£1.01 on 26 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
分析記事 • Nov 20Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)Olav Hellebo has been the CEO of ReNeuron Group plc (LON:RENE) since 2014, and this article will examine the...